Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

국소적으로 진행된 식도암에서 동시항암화학방사선치료의 결과

  • Byun, Sang-Jun (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Jin-Hee (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Ok-Bae (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Song, Hong-Suk (Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine)
  • 변상준 (계명대학교 의과대학 동산의료원 방사선종양학교실) ;
  • 김진희 (계명대학교 의과대학 동산의료원 방사선종양학교실) ;
  • 김옥배 (계명대학교 의과대학 동산의료원 방사선종양학교실) ;
  • 송홍석 (계명대학교 의과대학 동산의료원 내과학교실)
  • Received : 2010.11.17
  • Accepted : 2011.01.19
  • Published : 2011.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study was designed to evaluate the results of local control, survival rate, prognostic factors, and failure pattern in locally advanced esophageal cancer. Materials and Methods: We retrospectively studied 50 patients with locally advanced esophageal cancer treated with concurrent chemoradiotherapy at Keimyung University Dongsan Medical Center from June of 1999 to August of 2008. Seven patients with inappropriate data were excluded, and 43 patients were analyzed. There were 39 males and four female patients ranging in age from 43 to 78 years (median, 63 years). There were seven patients with stage IIA and 36 with stage III. Irradiation from 46 Gy to 63 Gy (median, 54 Gy) was carried out 5 days per week, 1.8 Gy once a day. There were eight patients with neo-adjuvant chemotherapy, and we mostly used 5-fluorouracil, cisplatin with 3 cycles for concurrent chemotherapy. The range of follow up periods was from 2 to 82 months (median, 15.5). Results: There were nine patients that exhibited a cornplete response, 23 that exhibited a partial response, 9 that exhibited no response, and 2 that exhibited disease progression. The median survival time was 15 months. Two-year and 5-year survival rates were 36.5% and 17.3%, respectively. Two-year and 5-year disease-free survival rates were 32.4% and 16%, respectively. Treatment failure occurred in 22 patients (51.2%). Patterns of failure were categorized as local failure in 18 patients and distant metastasis in four patients. In a univariate analysis for prognostic factors related to overall survival and disease-free survival, the hemoglobin levels during chemoradiotherapy (${\geq}$ 12 vs. <12, p=0.02(p=0.1) and the response to the treatments (CR/PR vs. NR/PD, p=0.002/p< 0.0001) were statistically significant. In a multivariate analysis, only response to the treatments was revealed to be statistically significant. There was no statistical significance associated with patient age, gender, disease stage, T-stage, smoking history, tumor location, or neo-adjuvant chemotherapy. Conclusion: Our survival rate was similar to those of other institutions. Local recurrence was the main reason for failure. It is suggested that further prospective studies should be performed to improve local control.

목 적: 국소적으로 진행된 식도암에서 동시항암화학요법 후 국소제어, 생존율, 예후인자 및 실패양상에 대해 알아 보고자하였다. 대상 및 방법: 1999년 6월부터 2008년 8월까지 계명대학교 동산의료원에서 국소적으로 진행된 식도암으로 진단받은 후, 근치적 목적의 동시항암화학방사선치료를 시행 받은 50명 중 추적검사가 이루어지지 않은 2명과 적절한 추적검사가 이루어지지 않아 치료의 효과를 판정할 수 없는 5명은 제외한 43명을 대상으로 하였다. 성별 구성은 남성 39명, 여성 4명이었고 연령분포는 43세에서 78세(중앙값, 63세), TNM 병기는 IIA기 7명(16.3%), III기 36명(83.7%)이었다. 방사선치료는 1.8 Gy씩 1일 1회, 주 5회로 방사선을 46~63 Gy(평균, 54 Gy)의 외부방사선을 조사하였다. 선행 항암화학요법을 시행 받은 환자는 8명이었고 동시항암화학치료는 주로 5-fluorouracil, cisplatin을 3회 사용하였다. 추적관찰 기간은 2개월에서 82개월로 중앙값이 15.5개월이었다. 결 과: 전체환자 43명 중에서 완전 관해는 9명(20.9%), 부분 관해는 23명(53.5%), 무반응 9명(20.9%), 진행이 2명(4.7%)이었다. 전체 환자의 중앙생존기간은 15개월이었고, 2년 및 5년 전체생존율은 36.5%, 17.3%이었으며, 2년 및 5년 무병생존율은 각각 32.4%, 16%였다. 43영의 환자 중에서 22명 (51.2%)에서 치료 실패를 보였고, 치료 실패 양상으로는 국소 재발 및 진행이 18명(41.9%), 원격전이가 4명(9.3%)이었다. 전체생존율 및 무병생존율에 영향을 미치는 인자에 대한 단변량분석상 항암화학방사선치료 시의 혈색소 수치 (${\geq}$12 vs. <12, p=0.02/p=0.1)와 치료에 대한 반응 여부(완전관해 및 부분관해 vs. 무반응 및 병의 진행, p=0.002/p<0.0001)가 통계적으로 유의한 인자였다. 다변량분석에서는 치료에 대한 반응 여부만이 통계적으로 유의한 것으로 나타났다. 환자의 나이, 성별, 병기, 흡연의 과거력, 식도 내 종양의 위치 및 선행항암화학요법의 유무에 따른 유의한 차이는 관찰되지 않았다. 결 론: 국소적으로 진행된 식도암의 동시 항암화학방사선치료 후 생존율은 다른 연구들과 유사한 수준이며 주된 재발 양상은 국소 재발이었다. 그러므로. 국소제어율을 향상시키기 위한 추가적인 연구가 향후 필요할 것으로 생각된다.

Keywords

References

  1. Halperin EC, Perez CA, Brady LW. Perez and Brady's principles and practice for radiation oncology. 5th ed. New York: Lippincott Williams & Wilkins, 2008:1131-1153
  2. DeMeester TR, Barlow AP. Surgery and current management for cancer of the esophagus and cardia. Curr Probl Cancer 1988;12:243-328 https://doi.org/10.1016/S0147-0272(88)80002-3
  3. Harrison LB, Fogel TD, Picone JR, Fischer DB, Weissberg JB. Radiation therapy for squamous cell carcinoma of the esophagus. J Surg Oncol 1988;37:40-43 https://doi.org/10.1002/jso.2930370112
  4. Pearson JG. The value of radiotherapy in the management of squamous oesophageal cancer. Br J Surg 1971;58:794-798 https://doi.org/10.1002/bjs.1800581023
  5. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998;339:1979-1984 https://doi.org/10.1056/NEJM199812313392704
  6. Arnott SJ, Duncan W, Gignoux M, et al. Preoperative radiotherapy in esophageal carcinoma: a meta-analysis using individual patient data (Oesophageal Cancer Collaborative Group). Int J Radiat Oncol Biol Phys 1998;41:579-583 https://doi.org/10.1016/S0360-3016(97)00569-5
  7. Rich T. Chemoradiation in conservation therapy for esophageal cancer. Hematol Oncol Clin North Am 2001;15:291-302 https://doi.org/10.1016/S0889-8588(05)70213-6
  8. Hennequin C, Maylin C. Continuous radiosensitizing chemotherapy. Pathol Biol (Paris) 1999;47:279-281
  9. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999;281:1623-1627 https://doi.org/10.1001/jama.281.17.1623
  10. James K, Eisenhauer E, Christian M, et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91:523-528 https://doi.org/10.1093/jnci/91.6.523
  11. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-1598 https://doi.org/10.1056/NEJM199206113262403
  12. Smith TJ, Ryan LM, Douglass HO Jr, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:269-276
  13. Zenda S, Hironaka S, Boku N, et al. Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer. Dis Esophagus 2008;21:195-200 https://doi.org/10.1111/j.1442-2050.2007.00750.x
  14. Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999;53:99-104 https://doi.org/10.1016/S0167-8140(99)00139-5
  15. Menon C, Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer Lett 2005;221:225-235 https://doi.org/10.1016/j.canlet.2004.06.029
  16. Vaupel P. Prognostic potential of the pre-therapeutic tumor oxygenation status. Adv Exp Med Biol 2009;645:241-246 https://doi.org/10.1007/978-0-387-85998-9_36
  17. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy: an international multi-center study. Radiother Oncol 2005;77:18-24 https://doi.org/10.1016/j.radonc.2005.06.038
  18. Grigiene R, Aleknavicius E, Kurtinaitis J. Prognostic value of anemia for patients with cervical cancer treated with irradiation. Medicina (Kaunas) 2005;41:916-924
  19. Langendijk H, de Jong J, Wanders R, Lambin P, Slotman B. The importance of pre-treatment haemoglobin level in inoperable non-small cell lung carcinoma treated with radical radiotherapy. Radiother Oncol 2003;67:321-325 https://doi.org/10.1016/S0167-8140(03)00057-4
  20. Rades D, Schild SE, Bahrehmand R, Zschenker O, Alberti WA, Rudat VR. Prognostic factors in the nonsurgical treatment of esophageal carcinoma with radiotherapy or radiochemotherapy: the importance of pretreatment hemoglobin levels. Cancer 2005;103:1740-1746 https://doi.org/10.1002/cncr.20952
  21. Neuhof D, Neumayer F, Einbeck W, et al. Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. Acta Oncol 2005;44:168-173 https://doi.org/10.1080/02841860510029563
  22. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-2317 https://doi.org/10.1200/JCO.2005.00.034
  23. Noh OK, Je HU, Kim SB, et al. Results of definitive chemoradiotherapy for unresectable esophageal cancer. J Korean Soc Ther Radiol Oncol 2008;26:195-203 https://doi.org/10.3857/jkstro.2008.26.4.195
  24. Khurana R, Dimri K, Lal P, et al. Factors influencing the development of ulcers and strictures in carcinoma of the esophagus treated with radiotherapy with or without concurrent chemotherapy. J Cancer Res Ther 2007;3:2-7 https://doi.org/10.4103/0973-1482.31963

Cited by

  1. Survival in Patients Treated with Definitive Chemo-Radiotherapy for Non-Metastatic Esophageal Cancer in North-West Iran vol.14, pp.3, 2013, https://doi.org/10.7314/apjcp.2013.14.3.1677